Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Luotai is an oral soft capsule containing total saponins extracted from *Panax notoginseng* (PNS). It is primarily indicated for the treatment and prevention of cerebrovascular and cardiovascular diseases, including ischemic stroke, cerebral infarction, and angina pectoris. The active components, which include ginsenoside Rb1, ginsenoside Rg1, and notoginsenoside R1, exert therapeutic effects by inhibiting platelet aggregation, reducing blood viscosity, and improving microcirculation. Additionally, it exhibits neuroprotective properties by mitigating damage caused by cerebral ischemia. While originally developed by Kunming Pharmaceutical Group in China, it is distributed and marketed in Vietnam by Dong Do Pharmaceutical as a prescription medication.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Luotai.